Table of Content

1. Introduction to PDGFR Inhibitors
1.1 Overview
1.2 Evolution of PDGFR Inhibitors


2. PDGFR Inhibitors - Mechanism of Action
2.1 General Functions & Mechanism
2.2 Approved Drugs Mechanism of Action


3. PDGFR Potential Target for Leading Pathological Conditions


4. Role of PDGFR Inhibitors in Cancer


5. Global PDGFR Inhibitors Clinical Trials Insight
5.1 By Phase
5.2 By Development Status
5.3 By Region


6. Global PDGFR Inhibitor Market Insight
6.1 Market Overview
6.2 Current Market Scenario


7. PDGFR Inhibitor Regional Market Analysis
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 ROW


8. PDGFR Inhibitor Market Opportunity By Indication
8.1 Gastrointestinal Stromal Tumors
8.2 Glioma
8.3 Colorectal Cancer
8.4 Leukemia
8.5 Lung Cancer


9. Lartruvo (Olaratumab) 1st Approved PDGFR Inhibitor (2016) & Market Withdrawal (2019)
9.1 Overview
9.2 Dosage, Price & Sales Analysis


10. Ayvakit (Avapritinib) 2ND Approved PDGFR Inhibitor (2020)
10.1 Overview
10.2 Patents & Assignees


11. Ayvakit Commercial Insight
11.1 Price & Dosage
11.2 Sales Analysis


12. Qinlock (Ripretinib) 3rd Approved PDGFR Inhibitor (2020)
12.1 Overview
12.2 Patents & Assignees


13. Qinlock Commercial Insight
13.1 Price & Dosage
13.2 Sales Analysis


14. PDGFR Inhibitors Sales Forecast 2026
14.1 Ayvakit Sales Forecast
14.2 Qinlock Sales Forecast


15. PDGFR Inhibitor Future Market Perspectives


16. Global PDGFR Inhibitors Market Dynamics
16.1 Market Drivers
16.2 Market Challenges


17. Competitive Landscape
17.1 Arog Pharmaceuticals, Inc
17.2 AstraZeneca
17.3 Bayer
17.4 Blueprint Medicine
17.5 Boehringer Ingelheim
17.6 Clovis Oncology
17.7 Deciphera Pharmaceuticals
17.8 Eli Lilly
17.9 Gilead Sciences
17.10 Pfizer
17.11 Tyrogenex
17.12 Zai Lab



List of Tables

Table 4-1: Frequency of PDGFR by Cancer Types
Table 8-1: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026
Table 8-2: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026
Table 8-3: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026
Table 8-4: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026
Table 8-5: Global – Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 – 2026